Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03784014 2026-04-29

MULTISARC

Phase 3 Completed

603 enrolled

Sarcoma

Neoplasm Metastasis, Sarcoma

NCT03976323 2026-02-25

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Phase 3 Completed

1,003 enrolled 23 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

NCT03976362 2026-02-25

KEYLYNK-008

Phase 3 Completed

851 enrolled 25 charts

Tumor-Agnostic

Carcinoma

NCT02000622 2026-02-13

OlympiAD

Phase 3 Completed

302 enrolled 26 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT03534453 2025-07-10

L-MOCA

Phase 3 Completed

229 enrolled

Gynecologic

Ovarian Neoplasms

NCT03834519 2025-05-18

KEYLYNK-010

Phase 3 Completed

793 enrolled 23 charts

Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

NCT04456699 2024-10-29

LYNK-003

Phase 3 Completed

335 enrolled 19 charts

Gastrointestinal

Colorectal Neoplasms

NCT03402841 2024-08-21

OPINION

Phase 3 Completed

279 enrolled 17 charts

Gynecologic

Ovarian Neoplasms

NCT01924533 2024-03-22

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Phase 3 Completed

525 enrolled 26 charts

Gastrointestinal

Stomach Neoplasms

NCT02987543 2023-10-06

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Phase 3 Completed

387 enrolled 16 charts 1 FDA

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT02184195 2023-09-13

POLO

Phase 3 Completed

154 enrolled 20 charts 1 FDA

Gastrointestinal

Pancreatic Neoplasms

NCT03286842 2023-01-17

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

Phase 3 Completed

256 enrolled 17 charts

Breast

HER2-ve Metastatic Breast Cancer

NCT03106987 2022-10-07

OReO

Phase 3 Completed

220 enrolled 21 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT02477644 2022-08-02

PAOLA-1

Phase 3 Completed

806 enrolled

Gynecologic

Ovarian Neoplasms

NCT02282020 2022-07-26

SOLO3

Phase 3 Completed

266 enrolled 31 charts

Gynecologic

Ovarian Neoplasms

Clinical Trials

KEYLYNK-001

MULTISARC

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

KEYLYNK-008

OlympiAD

L-MOCA

KEYLYNK-010

LYNK-003

OPINION

Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

POLO

To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.

OReO

PAOLA-1

SOLO3